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ABSTRACT 
 The development of methods for Central Nervous System drug delivery is still a 
challenge, due to the diﬃculty to deliver drug molecules across the Blood-Brain barrier 
that prevents the access of 100% of large-molecule drugs and 98% of small-molecule 
drugs.  
 Diﬀerent methods have been tested with the goal to bypass the Blood-Brain 
Barrier, but they are either invasive, non-targeted or require the formulation of new 
drugs.  
 We hypothesized that the combination of two methods, Focused Ultrasound and 
Intranasal delivery, can reduce the disadvantages that other methods present and 
result in greater overall delivery, improved tissue penetration, and possibly enrichment 
of the therapeutic agent (i.e. targeting) in the desired location(s) in brain.  
 This pilot study was designed to test the performance characteristics of study 
designs, measures, procedures, recruitment criteria and operational strategies. 
 By doing an animal model with 12 rats, we achieved a simple and eﬃcient 
experimental method to apply Focused Ultrasound and Intranasal delivery combined 
and the only changes done between subjects were related to the quantity given, timings 
and concentration.  
 Gadolinium enhancement was detected along the olfactory pathway, reaching 
the main olfactory epithelium in all the rats and it was possible also to visualize ﬂux 
through the main olfactory bulb also. We also proved that all the intranasal delivered 
model drugs using Focused Ultrasound (Trypan Blue and Dextrans) bypassed the 
Blood-Brain Barrier, being in that case delivered in important areas in the brain, in 
the level of the Rostral Striatum and the Substantia Nigra, targets for Parkinson’s 
disease. 
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 The findings can corroborate the idea that Focused Ultrasound can enhance the 
delivery of drugs in the brain using Intranasal administration, providing a target 
outcome and more sensitive, which is valuable in brain applications. 
KEY-WORDS: Focused Ultrasound, Intranasal Delivery, Blood-Brain Barrier, 
Brain Drug Delivery, Parkinson’s disease. 
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RESUMO 
As doenças do sistema nervoso como as doenças de Alzheimer e Parkinson fazem parte 
das principais causas de incapacidade e morte, a nível mundial, estando a incidência 
das mesmas a aumentar associado a factores como o envelhecimento da população. 
Existe assim um enorme problema relacionado com a libertação de drogas para 
processos de controlo de doença nestes pacientes, estando sujeitos à existência de 
diversos mecanismos de protecção das estruturas inerentes ao sistema nervoso central. 
Um dos mais importantes é a barreira hematoencefálica que constitui um desaﬁo a 
ultrapassar aquando da entrega de drogas terapêuticas, impedindo a entrada de cerca 
de 100% das substâncias com maior peso molecular e de 98% para as restantes. 
Diversos métodos têm sido desenvolvidos de modo a contornar esta barreira, 
apresentando porém limitações relacionadas com o facto de serem invasivos, terem uma 
baixa especiﬁcidade, alta toxicidade, sendo assim necessária a procura de outras 
técnicas. 
A utilização de ultra-sons em medicina é vasta a nível de diagnóstico e 
terapêutico. São vários os efeitos biológicos associados à utilização de ultra-sons de alta 
frequência, sendo estes capazes de causar uma abertura temporária da barreira 
hematoencefálica de forma localizada, permitindo a entrega de drogas em regiões de 
interesse clínico. Este fenómeno deve-se às interações mecânicas causadas pelas ondas 
ultra-sónicas entre as estruturas vasculares e o tecido endotelial. Esta técnica é não 
invasiva, sendo um método transiente.  
Outro método não invasivo utilizado terapeuticamente é a  entrega de drogas 
por via intranasal, já que estes por esta via de administração, irão passar diretamente 
para o sistema nervoso central, por meio dos nervos olfactório e trigeminal. Porém esta 
técnica apresenta uma baixa eﬁciência, uma vez que apenas uma pequena fração da 
dose administrada chega  ao local de interesse.  
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O projeto experimental teve por base a combinação destes dois métodos não 
invasivos, ultra-sons de alta frequência e administração intranasal, considerando que 
por hipótese, este novo processo resultaria numa entrega mais eﬁciente em regiões de 
interesse no sistema nervoso central para a doença de Parkinson, ultrapassando as 
limitações que as técnicas apresentam separadamente.  
 Esta tese pretende descrever as atividades realizadas na dissertação do 
Mestrado Integrado em Engenharia Biomédica e Biofísica da Faculdade de Ciências da 
Universidade de Lisboa, no ramo de Sinais e Imagens médicas. Este projecto 
experimental realizou-se no grupo de Focused Ultrasound, da Universidade de Harvard, 
em Boston Estados Unidos da América, sobre a orientação do Professor Doutor 
Nathan McDannold e do Professor Doutor Nuno Matela.  
 A tese reﬂecte os métodos, resultados e conclusões de um estudo de 
experimentação associado a um modelo animal em ratos e ratinhos (com um total de 
12 animais) recorrendo a três drogas de teste: Gadavist®, Trypan Blue e Dextrans, de 
forma a determinar as condições ótimas de design experimental ao utilizar as técnicas 
de ultra-sons e administração nasal em simultâneo e quais as estruturas biológicas 
relacionadas com a sua aplicação. Para a veriﬁcar o sucesso da aplicação do método 
foram usadas imagens por ressonância magnética, de forma a veriﬁcar de que forma a 
droga passa através das estruturas nasais (no caso do uso da droga Gadavist®) e ainda 
para garantir a existência de disrupção da barreira hematoencefálica em locais de 
interesse para a doença de Parkinson. Recorreu-se ainda a técnicas de imagens de 
ﬂuorescência e de microscópio para veriﬁcar a presença in situ, no caso do uso de 
Trypan Blue e Dextrans.  
 Há uma enorme necessidade de veriﬁcar a eﬁcácia de sistemas de entrega de 
drogas no sistema nervoso central, sendo este um dos primeiros estudos feitos 
combinando ultra-sons de alta frequência focalizados e entrega intranasal para a 
entrega de drogas modelo sendo que muitos dos resultados foram analisados 
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empiricamente. Os resultados deste estudo piloto demonstram que relativamente à 
técnica intranasal, esta envolve as células do epitélio olfativo, sendo que um possível 
caminho subsequente será a passagem para os bolbos olfactórios. As imagens por 
ressonância magnética ao longo do tempo demonstram a intervenção de várias 
estruturas olfativas por meio do aumento do signal devido à presença do contraste 
Gadavist® nas mesmas. Observou-se ainda que o intervalo temporal mínimo necessário 
para que a droga modelo chegue a essas mesmas estruturas é de cerca de trinta 
minutos, sendo que se assume por hipótese que o transporte está essencialmente 
relacionado com processos de difusão. 
 Ao utilizar as drogas de teste Trypan Blue e Dextrans foi ainda possível 
estabelecer um protocolo de administração por via intranasal, determinando os tempos, 
quantidades e ainda posição do animal que optimizam o processo. Ao aplicar as 
técnicas de ultra-som e entrega nasal conjuntamente, existe uma maior quantidade de 
droga no hemisfério cerebral em que foram aplicados o ultra-sons de alta frequência e a 
entrega nasal quando comparado com o hemisfério contralateral (controlo), em que 
apenas se administrou a substância via nasal, sendo este facto comportável por 
observação de imagens de microscopia de ﬂuorescência e de uma câmera de 
ﬂuorescência. Recorreu-se a Imagens por Ressonância Magnética de modo a aferir a 
disrupção da barreira hematoencefálica nos locais de interesse: o corpo estriado e 
substância negra. 
 Os diversos resultados apresentados poderão ser indicadores de que o modelo 
em hipótese foi bem-sucedido, sendo que será necessário aumentar o número de 
animais testados de forma a reunir uma amostra estatisticamente signiﬁcativa para 
conﬁrmação das observações feitas no presente estudo. Foram analisados ainda outros 
factores de interesse na entrega de drogas no sistema nervoso central usando os dois 
métodos em conjuntos tais como a posição do animal aquando da entrega, sendo que 
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ﬁca por estabelecer um paralelismo entre a anatomia do rato e do Homem, sendo este 
factor importante ao prosseguir para uma fase clínica do estudo.  
 Estudos posteriores recorrendo a terapia génica serão efetuados pelo grupo, com 
o objetivo da utilização desta técnica mista aplicada a locais de interesse no cérebro 
para a doença de Parkinson, usando estes resultados preliminares como referência no 
estabelecimento do protocolo experimental ao nível de tempos de entrega, volumes, 
parâmetros dos ultra-sons, entre outros. 
Palavras-Chave: Ultrasons, Administração nasal, Barreira Hematoencefálica, Brain 
Drug Delivery, Parkinson’s disease. 
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1.CHAPTER 1: INTRODUCTION AND MOTIVATION OF THE 
STUDY 
1.1. Introduction 
This thesis is inserted in a Focused Ultrasound Foundation Research Award Program 
funded project entitled “Focused Ultrasound for Increased Delivery of Intranasal DNA 
Nanoparticles to Rat Brain”.  
 The hypothesis of the project is that Focused Ultrasound (FUS) combined with 
Intranasal (IN) delivery can result in greater overall delivery of drugs in the central 
nervous system (CNS), improving tissue penetration, and possibly enrichment of the 
therapeutic agent (i.e. targeting) in the desired locations in brain. It was a 
multidisciplinary collaboration project between the Brigham and Women’s Hospital, 
Harvard Medical School and the Northeastern University. The project consisted in a 
pilot study with the goal of determining the optimal experimental design to use 
simultaneously FUS combined with IN delivery of drugs in the treatment of CNS 
diseases in sites of interest.  
 This chapter is an overview of the project motivation, the aims and objectives. 
1.2. Motivation 
Brain and mind disorders actually aﬀect every year 1.5 billion people worldwide, and 
the number is expected to increase [1]. The neurodegenerative CNS diseases, such as 
Parkinson (PD) and Alzheimer’s disease (AD), are among the leading causes of 
disability and death in the developed world. While the number of deaths due to major 
disorders such as heart disease, stroke, and prostate cancer has decreased, deaths 
attributed to brain tumors have not improved and AD and PD deaths are on the rise.  
Besides the lost of lives associated to this kind of diseases, there is also a 
economic cost that is becoming to be a concern in terms of health and research policies 
(Figure 1). 
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Figure 1 - Economic Cost of Brain diseases. [2] 
 The development of methods for CNS drug delivery is still a challenge, due to 
the diﬃculty to deliver drug molecules across the Blood-Brain barrier (BBB) that adds 
a further pharmacokinetic hurdle. The BBB prevents the access of 100% of large-
molecule drugs and 98% of small-molecule drugs (usually deﬁned as smaller than 
around 500–600 Da in molecular weight (MW)) [3]. 
Several brain drug delivery methods have been developed to help assist drugs in 
circumventing these problems. Methods include direct intracerebral or 
intracerebroventricular injections, mixing or attaching agents with vasculature-
modifying chemicals (i.e., mannitol), and the chemical modiﬁcation of agents to be 
delivered through endogenous transport systems. However, many of these methods are 
either too invasive, limited in spatial speciﬁcity, too toxic to be considered or simply do 
not work for certain drugs. There is the need for the implementation of techniques that 
solve these constraints. 
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1.3. Background and Signiﬁcance 
A promising use of FUS in the treatment of CNS disorders is to enhance drug delivery 
by locally and temporally disrupt the BBB. The ultrasound exposure is combined with 
intravenously (IV) injected microbubbles (MB), and their mechanical interactions with 
the vasculature cause the loosening of the tight junctions between vascular endothelial 
cells (ECs), by stimulating transcytosis or by some as yet undetermined means, 
causing a transient opening in the BBB. Many previously BBB-impermeable molecules 
are delivered in the brain by using low acoustic pressures. 
 Another non-invasive approach for direct delivery to the brain of therapeutic 
macromolecules is by IN administration. Using this technique, the drugs bypass the 
BBB structures, entering directly to the CNS utilizing pathways along olfactory and 
trigeminal nerves innervating the nasal passages. It is a non-invasive method, but only 
a small fraction of the nasally administered dose reaches the brain, resulting in a low 
eﬃcient method.  
Within this work it is hypothesized that combination of the two methods, FUS 
and IN delivery, can reduce these disadvantages and result in greater overall delivery, 
improved tissue penetration, and possibly enrichment of the therapeutic agent (i.e. 
targeting) in the desired location(s) in brain. Our hypothesis is that disruption of the 
BBB includes not only changes to the endothelial cells – widening of tight junctions 
and inducement of active transport – but that it also alters the perivascular channels 
through which intranasally-delivered agents are thought to ﬂow. This alteration may 
arise as a physiological response to the mechanical stimulation provided by the 
oscillating MB in the bloodstream (similar to what may be inducing active transport). 
It may also be possible that disruption of the BBB results in increased ﬂuid 
extravasation from the blood vessels, which may aid in transporting substances out 
and away from the perivascular spaces. 
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 We investigated whether FUS can increase the delivery to the brain of diﬀerent 
drugs given by the IN route of administration. This pilot study was designed to test 
the performance characteristics and capabilities of study designs, measures, procedures, 
recruitment criteria, and operational strategies that are under consideration for use in 
a subsequent study after the optimization of the factors referenced.  
 Therefore, the study was divided in two projects: 
•Gadolinium tracer distribution in the brain after Intranasal delivery – with 
the goal of tracing the pathways that a IN delivered drug takes in the brain by using 
Gadavist® (a Gadolinium based contrast); 
•Focused Ultrasound IN enhanced Delivery – combining the two techniques 
using diﬀerent model drugs, to determine the optimal conditions for the application 
of this method. 
 This thesis is structured in 5 chapters: Chapter 2 introduces the concepts 
related to the physiology of the BBB and to the use of focused ultrasound and the 
intranasal delivery, Chapter 3 and 4 detail the methods used, the experimental design 
and the most relevant results. Chapter 5 and 6 are dedicated to the discussion of the 
outcome of the diﬀerent subjects and the conclusion summarizing the ﬁndings. 
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2.CHAPTER 2: REVIEW OF THE LITERATURE AND 
RELATED RESEARCH: CONCEPTUAL FRAMEWORK 
2.1.Target Drug Delivery to the Central Nervous System 
2.1.1. Structure and function of the blood–brain barrier  
There are several mechanisms to guarantee brain’s homeostasis that includes the 
Blood-Cerebrospinal ﬂuid (CSF) interface formed by epithelial cells of the choroid 
plexus, the CSF-blood interface where the avascular arachnoid epithelium lies under 
the dura and encases the brain and one of the most important barriers, the BBB. This 
interface composes a high-density capillary network, providing blood supply to every 
neuron. 
The BBB is composed of a microvascular endothelium, astrocytes, basement 
membrane, pericytes and neurons that are in physical proximity to the endothelium, 
like is represented in Figure 2.  This structure regulates the passage of molecules by 
permiting the entry of nutrients and excluding harmful compounds, protecting the 
brain. It has selective substance permeability, excluding 98% of small-molecule drugs 
and approximately 100% of large-molecule neurotherapeutics from the brain 
parenchyma [5]. 
 Figure 2 – Normal conﬁguration of the BBB [4]. 
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 The selectivity is maintained by various transport functions of the otherwise 
very tight membrane. Eﬄux transporters also protect the brain from unwanted 
chemical inﬂuence, with P-glycoprotein (P-gp) as the best-known example [6]. 
Because of this ﬁltration process, most therapeutic agents do not enter the 
CNS, based in characteristics of the drug like its MW and also by molecular 
characteristics like charge, structure and degree of protein binding. 
2.1.2.BBB targeting strategies and related drug delivery systems 
There are several types of methods to deliver drugs through the BBB (Figure 3). The 
most important factors are the time frame of the treatment application and the need 
to transpose the BBB and its mechanisms of ﬁltering selectively the compounds. 
The most used approaches in the treatment of CNS diseases are to administer 
drugs intravenously or orally that will be distributed systemically and not only in the 
area to treat. Diﬀerent treatments are being implemented, and those methods are to 
circumvent the BBB, by delivering drugs directly into the brain parenchyma and to 
disrupt the BBB, by modulating a temporary opening of the barrier. The problem with 
methods to circumvent, like convection-enhanced delivery (a therapeutic agent is 
pumped directly into brain tissue through a ﬁne needle or cannula that is inserted into 
the brain through a small hole in the skull) is that it is an invasive approach. 
Figure 3 - Current approaches for CNS drug delivery. 
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Led by Prof. Elisa Konofagou, the Ultrasound Elasticity Imaging Laboratory of 
Columbia University, New York, has been pursuing methods of targeted drug delivery 
to the brain by opening the BBB with FUS [7],[8]. They were the ﬁrst demonstrated 
that FUS combined with IN technique is potentially useful for treating CNS diseases 
[3]. In the study, 40-kDa ﬂuorescently labeled dextran as the model drug and FUS was 
targeted at one region within the caudate putamen of mouse brains.  
The results showed that FUS combined with IN enhanced drug delivery within 
the targeted region compared with that achieved by IN only and that the delivery 
eﬃciency of FUS and IN combined was not signiﬁcantly diﬀerent from that of FUS and 
IV. This was a ﬁrst eﬀort, and more studies are necessary to optimize the FUS and IN 
treatment parameters for eﬃcient drug delivery. 
2.2. Focused Ultrasound 
2.2.1. Physical Principles 
Acoustic waves are organized and mechanical vibrations of molecules or atoms that can 
travel through media (gases, liquids, and solids). Ultrasound is an example of an 
acoustic wave which oscillations are generated by a transducer and transmitted 
sinusoidally within the medium, alternating local regions of compression (positive 
pressure) and rarefaction (negative pressure along the direction of propagation). This 
pressure wave oscillates at a frequency above 20 kHz or 20000 cycles per second and 
for medical applications, these frequencies are usually above 1 MHz and can be used to 
predict the way which ultrasound propagates and interacts with the tissue by knowing 
of the wave properties such as velocity, absorption, attenuation or reﬂection. 
The wavelength (λ) of the ultrasound is determined by the frequency (f) and 
the velocity ( ) for a given medium according to the following mathematical expression: 
      
          (1) 
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 A transducer with a spherical segment can focus ultrasonic waves, making them 
converge by transferring the energy to a focal region, providing high gains. The 
conﬁguration of the transducer is represented in Figure 4. 
Figure 4 - Diagram of a focused ultrasound transducer. [9] 
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2.2.2.FUS for BBB disruption  
2.2.2.1.Mechanism – Ultrasound and Microbubbles 
The use of focused ultrasound with microbubbles is a noninvasive approach to deliver 
drugs by inducing targeted BBB disruption for a certain period of time (few hours). 
This method uses the mechanical interactions (scattering, absorption of ultrasound and 
bubble oscillation) created by the ultrasound ﬁeld between the microbubbles oscillating 
and the vasculature, leading to a transient disassembly of tight junction complexes and 
the induction of active transport [10].   
In 2000, Professor Nathan McDannold and his laboratory at Brigham and 
Women’s Hospital found that if short ultrasound bursts are preceded by an intravenous 
injection of microbubbles contrast agent, the BBB could be consistently opened 
without the production of lesions or apparent neuronal damage. The BBB opening 
occurs using sonications applied as short (~1–20 milliseconds) bursts and at a low duty 
cycle (1–5%) for 0.5–1 minutes [5]. 
In a physiological context, modeling the MBs behavior is dependable on the 
assumptions made, which are related to the acoustic pressure.  
At low acoustic pressures, stable cavitation causes MBs to oscillate linearly with 
the incident amplitude of the applied ultrasound pulse, resulting in the generation of 
not only nonlinear harmonic ultrasound waves of the transmitted fundamental 
frequency (i.e., half the fundamental frequency - subharmonics - 2-fold of the 
fundamental frequency - second harmonics - etc.), but also causes shear stresses around 
the MBs (e.g., microstream)[9][11]. The equation of bubble motion can be modeled as: 
    
           (2) 
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where m is the mass of the bubble–liquid system, b is the mechanical resistance related 
to the dissipation, S is the stiﬀness of the system, Fdriv(t) is the driving force, and x(t) 
is the radial displacement of the bubble wall relative to the initial radius R0, according 
to: 
x(t) = R(t) - R0  (3) 
 Equation 2 was formulated considering the following assumptions [9]: 
a. A bubble is considered spherical and surrounded by a liquid of inﬁnite extent 
and a constant viscosity. The bubble volume is deﬁned by a single variable, the 
radius and the motion of bubble is spherically symmetric; 
b. The wavelength of the ultrasound ﬁeld is much larger than the bubble diameter, 
and the motion of the bubble surface is only of interest. The vapor pressure 
remains constant during the compression and expansion phase and that there is 
no rectiﬁed diﬀusion during the short period of exposure to ultrasound; 
c. The gas inside the bubble is assumed to be ideal and compression and 
expansion takes place according to the gas law; 
d. At small excitation levels, the displacement of the bubble wall can be compared 
to the displacement of a simple one-dimensional mass spring oscillator. The 
oscillator is deﬁned by its mass, restoring force, damping, and applied force. 
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 At higher acoustic pressures, a more sophisticated model is needed once the 
MBs become instable and grow rapidly during the rarefaction phase of ultrasound and 
violently collapse due to the inertia of the ﬂuid. This type of cavitation is referred to as 
inertial cavitation. The collapse of MBs splits them into many smaller MBs and even 
fragmentations, producing wideband signals that are usually recognized as a signature 
of inertial cavitation.  
(4) 
where R, dR/dt, dR2/dt2 represent the radius, velocity and acceleration of the 
bubble wall, r is the density of the liquid,     is the ambient pressure, s is the surface 
 tension, k is the polytropic gas exponent, m is the viscosity of the surrounding water, 
 c is the speed of sound, and Pac(t) is the applied acoustic ﬁeld.  
For the nonlinear Bubble Vibration following the next assumptions were used [9]: 
a. The bubble is spherical and surrounded by an incompressible liquid with 
constant viscosity to inﬁnite extent; 
b. The gas in the bubble is compressed and expanded according to the gas law with 
the polytropic exponent remaining constant during the vibration; 
c. Pressure at the bubble wall is at equilibrium. Combining the Rayleigh–Plesset 
equation and the polytropic gas law with the boundary condition, Nico-de Jong. 
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2.2.2.2.Correlation of Ultrasound Parameters on BBB Disruption 
The use of ultrasound and microbubbles can produce BBB disruption, but there is still 
a concern about the bio eﬀects produced by inertial cavitation, that can cause damage 
to cellular structures, producing undesired situations like intracerebral hemorrhage, per 
example. 
A number of sonication parameters can be varied in ultrasonic BBB disruption. 
Each parameter variation may impact the threshold pressure amplitude needed to 
disrupt the BBB, along with the magnitude of its disruption, and the resultant drug 
quantity delivered to the brain parenchyma. For a ﬁxed set of parameters, the 
magnitude of the BBB disruption is proportional to the increase of the pressure 
amplitude and to the sonication duration. Other parameters that inﬂuence the BBB 
opening threshold are the ultrasound frequency and the burst length. Several 
experiments [12][13][14] showed that it is possible to achieve eﬀectively BBB 
disruption, by using a reliable group of settings [5], even without knowing the exact 
mechanism by which microbubble-enhanced FUS induces BBB disruption. 
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2.3. Intranasal drug delivery 
2.3.1.Physiological principles - Nasal Pathways 
The intranasal route of administration it is a non-invasive method by which 
therapeutic biomolecules can be delivered directly to the CNS, bypassing the BBB. 
The mechanisms underlying nose-to-brain transport have been widely investigated, but 
still unknown. Brieﬂy, nasally administered substances follow the trajectory of the 
olfactory and trigeminal nerve pathways, by transcellular and extracellular processes. 
Transcellular transport involves neuronal uptake and retrograde transport within 
axons, a slow process that can take several days. However, transport of intranasally 
administered substances into the brain can occur within minutes.  
Both nerves originate in the nasal cavity, having a ﬁrst contact with the nasal mucosa. 
The olfactory pathway begins in the upper nasal passages, where olfactory receptor 
neurons extend from the mucus layer of the olfactory epithelium, through the lamina 
propria and cribiform plate, and into the CSF-ﬁlled subarachnoid space of the cranial 
cavity.  Once substances reach the CSF, they can travel in perivascular spaces formed 
between the outer membrane of microvessels and basement membrane of neighboring 
tissue, such as the glial basement membrane, which is comprised of astrocyte endfeet. 
These perivascular channels are thought to be the conduits through which intranasally 
delivered substances are distributed throughout the brain. Bulk ﬂow mechanisms and 
arterial pulsations create a driving force for this ‘perivascular pump’. 
The trigeminal nerve, on the other hand, originates in the respiratory region of 
the nasal passages and enters the CNS at two points: i) the anterior lacerated foramen 
located near the pons; and ii) the cribiform plate near the olfactory bulbs. Thus, 
intranasally administered substances can reach both caudal and rostral brain regions 
by following the trajectory of the trigeminal nerve. The blood supply to the respiratory 
epithelium is relatively greater compared to the olfactory epithelium, making it an 
ideal site for systemic absorption of nasally applied drugs. Figure 5 represents the a 
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anatomical areas related to the nasal delivery. 
Figure 5 - Nasal Pathways. [15] (A) Dashed lines surrounding blood vessels represent the entering of 
the drugs in the perivascular channels and the dashed arrows pathways involving the olfactory and 
trigeminal nerves; (B)  After reaching the lamina propria, they can access the cerebrospinal ﬂuid 
(CSF) and olfactory bulbs (dashed arrows). 
In accordance to the studies of Professor Barbara Waszczak [16], although nose-
to-brain transport is rapid, only a small percentage of the total intranasally 
administered dose successfully reaches the brain, that is, delivery to brain was 
estimated to be about 1% of the administered dose in animal studies. 
 Animal models have been tested, and it is possible to notice the diﬀerences of 
the characteristics of the nasal cavity between Humans and rats (Table 1). This can be 
a factor to take in consideration in the results, once there are some anatomical 
diﬀerences between the animal model used for the intranasal delivery and Humans and 
it will be always necessary clinical trials to prove that the mechanisms involved are the 
same and the conclusions can be extrapolated. 
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Table 1 - Characteristics of nasal cavity between Human and rat[17].  
2.3.2.Factors that can inﬂuence the delivery by the IN route 
There are several important factors to have in consideration in order to drugs to be 
delivered to the CNS via a nasal route. To achieve an eﬃcient and rapid deposition of 
the drug, it needs to transverse the nasal mucosa, which is inﬂuenced by many factors 
such as mode of administration, particle size of the formulation, velocity of the 
delivered particles and angle [15] 18] [19]. 
 In the choice of a model drug, it is important to have in consideration the 
physicochemical properties of the formulation, which are critical in terms of the 
regulation of its absorption when intranasally administrated. From the literature, it is 
known that for compounds with a MW up to 300 Da, the absorption of the drug 
decreases with the increase of the MW and the inverse can be noticed for compounds 
with a MW greater than 1000 Da [17]. 
Particle size and shape is another critical parameter in the design of nasal drug 
delivery systems, as particles with a diameter greater than 10 μm remain in the nasal 
cavity and small particles in general tend to go all the way through the nasal passage 
to the throat and lungs. Particles with diameters of less than 5 μm were deposited in 
the alveoli region, those with diameters between 5 and 10 μm were deposited into the 
bronchi, and those with diameters of > 10 μm were localized and distributed within 
the nasal cavities [17]. This can be an important fact in the choice of the model drug, 
once we are interested in the nasal pathways that go to the CNS, instead of the 
deposition of the substance in diﬀerent locations of the respiratory system. 
Nasal Cavity Human Rat
Length (cm) 7.5 2.3
Volume (cm3) 20.0 0.4
Surface area (cm2) 150.0 14.0
Olfactory area (cm2) 10.0 7.0
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